The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2008
At a glance
- Drugs NB 001 (Primary)
- Indications Herpes labialis
- Focus Adverse reactions; Therapeutic Use
- Sponsors NanoBio Corporation
- 28 Oct 2008 Data presented at the annual ICAAC/IDSA meeting in Washington, D.C, USA.
- 17 Mar 2008 Primary endpoint met; results reported in a NanoBio Corporation media release.
- 17 Mar 2008 Status change from in progress to completed, based on a NanoBio media release.